Showing 3301-3310 of 6035 results for "".
- AAO Launches New Scientific Journal Dedicated to Glaucoma Researchhttps://modernod.com/news/aao-launches-new-scientific-journal-dedicated-to-glaucoma-research/2479972/The American Academy of Ophthalmology announced the launch of Ophthalmology Glaucoma, a scientific journal focused exclusively on glaucoma. As development of next-generation glaucoma devices and drugs surges, Ophthalmology Glaucoma offers researchers an expanded opportunity to pu
- Topical Presbyopia Treatment Advances in Clinical Developmenthttps://modernod.com/news/presbyopia-therapies-announces-primary-safety-and-efficacy-resutls-in-phase-2b-study-of-topical-presbyopia-treatment/2479978/Presbyopia Therapies announced that the primary efficacy and safety endpoints have been met in a phase 2b study of its PRX ophthalmic solution. PRX demonstrated a 3 line or greater improvement in monocular distance corrected near acuity in patients between the ages of 48 and 64, with this improve
- OCT Angiography Predicts Exudation in Macular Degenerationhttps://modernod.com/news/oct-angiography-predicts-exudation-in-macular-degeneration/2479981/Optical coherence tomography (OCT) angiography can help predict which eyes affected by age-related macular degeneration are most likely to develop exudation, research shows, according to a report in Medscape. The new technology can
- State Strips Ex-USC Medical School Dean of License, Citing ‘An Appalling Lack of Judgment’https://modernod.com/news/state-strips-ex-usc-medical-school-dean-of-license-citing-an-appalling-lack-of-judgment/2479992/The California state agency that regulates physicians ordered USC’s former medical school dean stripped of his license to practice medicine, citing “an appalling lack of judgment” in his use of drugs an
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Heidelberg Engineering Announces Leadership Changeshttps://modernod.com/news/heidelberg-engineering-announces-leadership-changes/2480004/Heidelberg Engineering announced changes to the leadership team. Ali Tafreshi who has served in sales, marketing and research capacities in both the United States and German organizations
- Alzheimer’s Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Boardhttps://modernod.com/news/alzheimers-therapeutics-research-leader-dr-roy-twyman-joins-neurovision-imaging-board/2480013/Roy Ervin Twyman, MD, PhD, an academic neurologist with nearly 20 years’ experience in neuroscience pharmaceutical drug development, will join the NeuroVision Imaging Board of Directors on July 20. NeuroVision is developing and studying an experimental, breakthrough, low-cost, noninvasive,
- Sue Anschutz-Rodgers Eye Center: A Highly Visible Legacy of Longstanding Philanthropic Partnershiphttps://modernod.com/news/sue-anschutz-rodgers-eye-center-a-highly-visible-legacy-of-longstanding-philanthropic-partnership/2480040/The University of Colorado Anschutz Medical Campus and UCHealth announced the naming of the UCHealth Eye Center program for philanthropist Sue Anschutz-Rodgers, who has made leadership gifts to accelerate innovative r
- Retinal Thinning Tied to Cognitive Declinehttps://modernod.com/news/retinal-thinning-tied-to-cognitive-decline/2480058/Thinning of the eye’s retinal nerve fiber layer (RNFL) appears to be a strong predictor of cognitive decline, new research shows, according to a report in Medscape. Investigators found healthy individuals with RNFL thinning w
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a